- Home
- / Verastem Oncology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CreditSafe score
?
Score changed on Feb 02, 2023
Premium Content
Learn moreFinancial statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
| Revenue | 26.7M | 17.5M | 88.5M | 2.1M |
| Revenue growth, % | -34.7% | 407.1% | ||
| Cost of goods sold | 165.0K | 2.8M | 33.7M | |
| Gross profit | 26.6M | 14.6M | 54.8M | |
| Gross profit margin, % | 99.4% | 83.9% | 61.9% | |
| General and administrative expense | 77.3M | 101.2M | 62.8M | 24.1M |
| Operating expense total | 121.3M | 147.0M | 104.1M | |
| Depreciation and amortization | 423.0K | |||
| EBIT | (94.8M) | (132.3M) | (49.4M) | (61.4M) |
| EBIT margin, % | -354.8% | -758.1% | -55.8% | |
| Interest income | 2.6M | 4.4M | 515.0K | 181.0K |
| Interest expense | 5.8M | 20.6M | 15.8M | |
| Pre tax profit | (67.5M) | (71.2M) | ||
| Income tax expense | 194.0K | |||
| Net Income | (72.4M) | (149.2M) | (67.7M) | (71.2M) |
| EPS | (1.4) | (2.0) | (0.4) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension